{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:54:23Z","timestamp":1789152863130,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Progression of fibrotic interstitial lung disease (ILD) leads to irreversible loss of lung function and increased mortality. Based on an institutional ILD registry, we aimed to evaluate biomarkers derived from baseline patient characteristics, computed tomography (CT), and peripheral blood for prognosis of disease progression in fibrotic ILD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Of 209 subsequent ILD-board patients enregistered, 142 had complete follow-up information and were classified fibrotic ILD as defined by presence of reticulation or honeycombing using a standardized semi-quantitative CT evaluation, adding up typical ILD findings in 0\u20136 defined lung fields. Progression at 1 year was defined as relative loss of \u226510% in forced vital capacity, of \u226515% in diffusion capacity for carbon monoxide, death, or lung transplant. Two-thirds of the patients were randomly assigned to a derivation cohort evaluated for the impact of age, sex, baseline lung function, CT finding scores, and blood biomarkers on disease progression. Significant variables were included into a regression model, its results were used to derive a progression-risk score which was then applied to the validation cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the derivation cohort, age, monocyte count \u22650.65 G\/L, honeycombing and traction bronchiectasis extent had significant impact. Multivariate analyses revealed the variables monocyte count \u22650.65 G\/L (1 point) and combined honeycombing or traction bronchiectasis score [0 vs. 1\u20134 (1 point) vs. 5\u20136 lung fields (2 points)] as significant, so these were used for score development. In the derivation cohort, resulting scores of 0, 1, 2, and 3 accounted for 1-year progression rates of 20, 25, 46.9, and 88.9%, respectively. Similarly, in the validation cohort, progression at 1 year occurred in 0, 23.8, 53.9, and 62.5%, respectively. A score \u22652 showed 70.6% sensitivity and 67.9% specificity, receiver operating characteristic analysis for the scoring model had an area under the curve of 71.7%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The extent of honeycombing and traction bronchiectasis, as well as elevated blood monocyte count predicted progression within 1 year in fibrotic ILD patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1043720","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:22:07Z","timestamp":1668576127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases\u2014Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score"],"prefix":"10.3389","volume":"9","author":[{"given":"Guangyu","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Hawle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Horner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hintenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.chest.2017.05.015","article-title":"Lung manifestations in the rheumatic diseases.","volume":"152","author":"Doyle","year":"2017","journal-title":"Chest."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung Disease.","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis\u2013associated interstitial lung disease.","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease.","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases.","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"8","author":"Maher","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline.","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases.","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases.","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1183\/13993003.congress-2020.4576","article-title":"Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? ILD \/ DPLD of known origin.","volume":"56","author":"Chaudhuri","year":"2020","journal-title":"Eur Respir Soc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","article-title":"Treatment of fibrotic interstitial lung disease: current approaches and future directions.","volume":"398","author":"Johannson","year":"2021","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases.","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann Am Thorac Soc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12890-017-0418-2","article-title":"Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis.","volume":"17","author":"Jacob","year":"2017","journal-title":"BMC Pulm Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"keac184","DOI":"10.1093\/rheumatology\/keac184","article-title":"Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease.","volume":"18","author":"Oh","year":"2022","journal-title":"Rheumatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis.","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2100221","DOI":"10.1183\/13993003.00221-2021","article-title":"The burden of progressive fibrotic interstitial lung disease across the UK.","volume":"58","author":"Simpson","year":"2021","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis.","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.chest.2021.01.026","article-title":"Family history of pulmonary fibrosis predicts worse survival in patients with interstitial lung disease.","volume":"159","author":"Cutting","year":"2021","journal-title":"Chest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis.","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease.","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"147997312096702","DOI":"10.1177\/1479973120967025","article-title":"Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases\u2014Network-analyses and multivariate models.","volume":"17","author":"Lang","year":"2020","journal-title":"Chron Respir Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00408-021-00434-w","article-title":"Computed tomography findings as determinants of local and systemic inflammation biomarkers in interstitial lung diseases: A retrospective registry-based descriptive study.","volume":"199","author":"Lang","year":"2021","journal-title":"Lung."},{"key":"B32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.chest.2019.10.017","article-title":"An algorithmic approach to the interpretation of diffuse lung disease on Chest CT Imaging :A theory of almost everything.","volume":"157","author":"Gruden","year":"2019","journal-title":"Chest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejrad.2017.03.018","article-title":"Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern.","volume":"91","author":"Kim","year":"2017","journal-title":"Eur J Radiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official european respiratory society\/american thoracic society research statement: interstitial pneumonia with autoimmune features.","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J."},{"key":"B36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. report working party standardization of lung function tests, european community for steel and coal. official statement of the european respiratory society.","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J. Suppl"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis.","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.","volume":"46","author":"Behr","year":"2015","journal-title":"Eur Respir J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD).","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD \u2013 achievements and ambiguity in a devastating disease.","volume":"21","author":"Hoffmann-Vold","year":"2020","journal-title":"Respir Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease.","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","article-title":"Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study.","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1007\/s12325-022-02145-x","article-title":"Meta-Analysis of effect of nintedanib on reducing FVC decline across interstitial lung diseases.","volume":"39","author":"Bonella","year":"2022","journal-title":"Adv Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS\u00a7trials.","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"210011","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management.","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","article-title":"Diagnosis and treatment of fibrotic hypersensitivity pneumonia. where we stand and where we need to go.","volume":"196","author":"Salisbury","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu","year":"2012","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis.","author":"Pugashetti","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.chest.2019.06.035","article-title":"Diffusing capacity of carbon monoxide in assessment of COPD.","volume":"156","author":"Balasubramanian","year":"2019","journal-title":"Chest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/jcm11010132","article-title":"Carbon monoxide diffusion capacity as a severity marker in pulmonary hypertension.","volume":"11","author":"Diamanti","year":"2021","journal-title":"J Clin Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","article-title":"Prevalence and prognosis of unclassifiable interstitial lung disease.","volume":"42","author":"Ryerson","year":"2013","journal-title":"Eur Respir J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","article-title":"Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.","volume":"22","author":"Qiu","year":"2021","journal-title":"Respir Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1148\/radiol.12112516","article-title":"Interobserver variability in the CT Assessment of Honeycombing in the Lungs.","volume":"266","author":"Watadani","year":"2013","journal-title":"Radiology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants.","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax."},{"key":"B58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2213-2600(18)30508-3","article-title":"Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.","volume":"7","author":"Scott","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1183\/13993003.congress-2020.722","article-title":"The role of monocyte count on monitoring patients with Idiopatic Pulmonary Fibrosis under antifibrotic treatment.","volume":"56","author":"Ara\u00fajo Barros Coelho","year":"2020","journal-title":"Eur Respir Soc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More Than Suppression: Glucocorticoid action on monocytes and macrophages.","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Front Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12967-021-02744-2","article-title":"Combined lymphocyte\/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.","volume":"19","author":"Biamonte","year":"2021","journal-title":"J Transl Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12879-022-07450-y","article-title":"Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls.","volume":"22","author":"Knudsen","year":"2022","journal-title":"BMC Infect Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12967-014-0375-y","article-title":"The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis.","volume":"13","author":"Chara","year":"2015","journal-title":"J Transl Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"7561661","DOI":"10.1155\/2022\/7561661","article-title":"Methotrexate treatment suppresses monocytes in nonresponders to pneumococcal conjugate vaccine in rheumatoid arthritis patients.","volume":"2022","author":"Elm\u00e9r","year":"2022","journal-title":"J Immunol Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1043720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:22:13Z","timestamp":1668576133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1043720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":64,"alternative-id":["10.3389\/fmed.2022.1043720"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1043720","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1043720"}}